Treatment
Cabotegravir clinical trials
We’re tracking 20 recruiting studies that include Cabotegravir, each written for real people, not researchers, below.
Recruiting studies
- NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT06646562RecruitingPhase 4
Long-acting injectable HIV meds for adults 60 and older
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Elche, AlicanteAges 60 years+ - NCT07672717RecruitingPhase 1
Cabotegravir and hormone interaction study for HIV prevention
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
Baltimore, MarylandAges 19 years+ - NCT05515770RecruitingPhase 3
Injectable PrEP shot for HIV prevention in higher-risk adults
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Rio de JaneiroAges 18–30 - NCT06405464Recruiting
Long-acting HIV shots vs daily pills in the Swiss HIV Cohort
This study looks at how well the long-acting injectable HIV treatment (cabotegravir plus rilpivirine) works in real life, compared to daily pills. It follows people in the Swiss HIV Cohort Study to understand who benefits most and why.
ZurichAges 18 years+ - NCT06807736Recruiting
Choosing injectable PrEP for HIV prevention in Cape Town
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Cape Town, Western ProvinceAges 15 years+ - NCT07199335RecruitingPhase 4
Injectable HIV prevention drug for people who inject drugs
This study tests a long-acting injectable medication called cabotegravir to prevent HIV in people who inject drugs. If you have injected street drugs recently, you may be able to get this shot every few months instead of taking daily pills.
Boston, MassachusettsAges 18 years+ - NCT07370649Recruiting
Long-acting HIV injectable study for subtype A6
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
PragueAges 18 years+ - NCT07473778Recruiting
Study of Lenacapavir for HIV Prevention
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Birmingham, AlabamaAges 18 years+ - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+ - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT06485154RecruitingPhase 4
Finding the best HIV treatment after PrEP shot failure
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
Johannesburg, GautengAges 15 years+ - NCT07221747Recruiting
PERSIST trial: PrEP injections for HIV prevention
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
LilongweAges 15–110 - NCT06474364RecruitingPhase 4
HIV prevention and care for youth in Uganda
This study tests ways to help young people in Uganda prevent HIV or stay healthy if they already have HIV. It offers free prevention pills or injections and care for those living with HIV.
KampalaAges 15–24 - NCT07579754Recruiting
Understanding Women's HIV Prevention Medicine Choices in Malawi
This study aims to understand why some women in Malawi stopped taking PrEP (a medicine that prevents HIV) and what could help them stay on treatment. Researchers will contact women who started PrEP but missed their appointments to learn about their experiences and barriers.
BlantyreAges 18–110 - NCT05044962Recruiting
Study birth control timing in HIV, using blood tests
This study looks at how well HIV treatment (ART) and a hormonal birth control method (DMPA shot or implant) work together, using small blood samples. It may help ensure safer, more effective HIV care and contraception for young women.
Eldoret, KenyaAges 15–24 - NCT05663580Recruiting
Study of HIV treatment with long-acting injected medicines
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
MilanAges 18 years+ - NCT06250504RecruitingPhase 3
HIV prevention study for young adults
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
Somkele, KwaZulu-NatalAges 15–30 - NCT07275606RecruitingPhase 1/Phase 2
Testing HIV prevention medicine cabotegravir in newborns
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Parow ValleyAges Up to 1 week
What Cabotegravir is being studied for
Conditions with recruiting Cabotegravir studies.
Common questions
- Are there clinical trials studying Cabotegravir?
- Yes. Clin2 currently lists 20 recruiting studies that include Cabotegravir, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cabotegravir trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cabotegravir an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cabotegravir or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.